Mast cell activation syndrome: Proposed diagnostic criteria. 2010

Cem Akin, and Peter Valent, and Dean D Metcalfe
Department of Internal Medicine, Division of Allergy and Immunology, University of Michigan, Ann Arbor, MI, USA.

The term mast cell activation syndrome (MCAS) is finding increasing use as a diagnosis for subjects who present with signs and symptoms involving the dermis, gastrointestinal track, and cardiovascular system frequently accompanied by neurologic complaints. Such patients often have undergone multiple extensive medical evaluations by different physicians in varied disciplines without a definitive medical diagnosis until the diagnosis of MCAS is applied. However, MCAS as a distinct clinical entity has not been generally accepted, nor do there exist definitive criteria for diagnosis. Based on current understanding of this disease "syndrome" and on what we do know about mast cell activation and resulting pathology, we will explore and propose criteria for its diagnosis. The proposed criteria will be discussed in the context of other disorders involving mast cells or with similar presentations and as a basis for further scientific study and validation.

UI MeSH Term Description Entries
D008407 Mast Cells Granulated cells that are found in almost all tissues, most abundantly in the skin and the gastrointestinal tract. Like the BASOPHILS, mast cells contain large amounts of HISTAMINE and HEPARIN. Unlike basophils, mast cells normally remain in the tissues and do not circulate in the blood. Mast cells, derived from the bone marrow stem cells, are regulated by the STEM CELL FACTOR. Basophils, Tissue,Basophil, Tissue,Cell, Mast,Cells, Mast,Mast Cell,Tissue Basophil,Tissue Basophils
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000015 Abnormalities, Multiple Congenital abnormalities that affect more than one organ or body structure. Multiple Abnormalities
D013577 Syndrome A characteristic symptom complex. Symptom Cluster,Cluster, Symptom,Clusters, Symptom,Symptom Clusters,Syndromes
D015230 Prostaglandin D2 The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects. 11-Dehydroprostaglandin F2alpha,PGD2,11-Dehydroprostaglandin F2 alpha,11 Dehydroprostaglandin F2 alpha,11 Dehydroprostaglandin F2alpha,D2, Prostaglandin,F2 alpha, 11-Dehydroprostaglandin,F2alpha, 11-Dehydroprostaglandin,alpha, 11-Dehydroprostaglandin F2
D015550 Cell Degranulation The process of losing secretory granules (SECRETORY VESICLES). This occurs, for example, in mast cells, basophils, neutrophils, eosinophils, and platelets when secretory products are released from the granules by EXOCYTOSIS. Degranulation, Cell
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine
D017410 Practice Guidelines as Topic Works about directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery. Clinical Guidelines as Topic,Best Practices,Best Practice
D017997 Leukotriene C4 The conjugation product of LEUKOTRIENE A4 and glutathione. It is the major arachidonic acid metabolite in macrophages and human mast cells as well as in antigen-sensitized lung tissue. It stimulates mucus secretion in the lung, and produces contractions of nonvascular and some VASCULAR SMOOTH MUSCLE. (From Dictionary of Prostaglandins and Related Compounds, 1990) LTC4,Leukotriene C,Leukotriene C-1,Leukotriene C-4,Leukotriene C1,Leukotrienes C,Leukotriene C 1,Leukotriene C 4

Related Publications

Cem Akin, and Peter Valent, and Dean D Metcalfe
January 2021, Frontiers in veterinary science,
Cem Akin, and Peter Valent, and Dean D Metcalfe
November 2002, European heart journal,
Cem Akin, and Peter Valent, and Dean D Metcalfe
February 2011, Journal of the American College of Cardiology,
Cem Akin, and Peter Valent, and Dean D Metcalfe
April 2010, The International journal of eating disorders,
Cem Akin, and Peter Valent, and Dean D Metcalfe
April 2023, Journal of personalized medicine,
Cem Akin, and Peter Valent, and Dean D Metcalfe
June 1999, The international journal of neuropsychopharmacology,
Cem Akin, and Peter Valent, and Dean D Metcalfe
February 2013, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
Cem Akin, and Peter Valent, and Dean D Metcalfe
June 2018, Clinical reviews in allergy & immunology,
Cem Akin, and Peter Valent, and Dean D Metcalfe
April 2020, Journal of the American Association of Nurse Practitioners,
Copied contents to your clipboard!